<DOC>
	<DOCNO>NCT00760370</DOCNO>
	<brief_summary>The investigator major aim determine whether difference retention zoledronic acid multiple myeloma patient , compare patient breast cancer metastasis bone . In addition investigator wish analyze retention zoledronic acid correlate extent bone resorption/formation , tendency change retention sequential treatment .</brief_summary>
	<brief_title>Comparison Zometa Retention Effect Multiple Myeloma Breast Cancer</brief_title>
	<detailed_description>The clinical benefit treatment bisphosphonates document large number clinical study , bisphosphonates widely use treatment pain prevention bone fracture vertebral collapse example patient cancer metastasis bone multiple myeloma . Repeated intravenous administration potent bisphosphonates ( pamidronate zoledronic acid ) often use treatment osteolytic disease cause disseminated cancer multiple myeloma , less potent oral bisphosphonates often prescribe treatment benign osteoporosis . The recommend dose time schedule treatment potent bisphosphonates base concern avoid toxicity time obtain maximal clinical benefit . Clinical study multiple myeloma bone metastasis show significant activity pamidronate ( 90 mg iv infusion 2-4 hour ) zoledronic acid ( 4 mg iv 15 min ) repeat every 4 week treatment period 9 month beyond , optimal duration treatment know . This particular important issue since use potent bisphosphonates bring connection osteonecrosis . In present study compare retention Zometa effect bone marker patient multiple myeloma breast cancer metastases bone .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients diagnose breast cancer metastases bone . Patients diagnose multiple myeloma . Patients schedule receive Zometa . Postmenopausal woman ( least 10 month since last period ) . Newly diagnose patient must clear sign osteolysis . Antiestrogen treatment . Patients give chemotherapy less 7 day study begin . Patients receive glucocorticoid le 5 day prior study begin study period ( 14 day )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>bone marker</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>Zometa</keyword>
	<keyword>retention</keyword>
	<keyword>breast cancer</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>CTX</keyword>
	<keyword>bone specific ALP</keyword>
</DOC>